Stock Analysis on Net

Cytokinetics Inc. (NASDAQ:CYTK)

This company has been moved to the archive! The financial data has not been updated since November 3, 2023.

Analysis of Liquidity Ratios
Quarterly Data

Microsoft Excel

Liquidity Ratios (Summary)

Cytokinetics Inc., liquidity ratios (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Current ratio 7.22 8.94 9.05 9.40 11.56 9.01 9.33 7.45 6.12 5.90 12.05 15.20 15.17 9.65 10.89 8.98 8.20 8.42 7.09 9.36 10.57 8.95 7.07
Quick ratio 6.97 8.64 8.84 9.25 11.37 8.80 9.20 7.28 5.91 5.72 11.97 15.02 15.06 9.49 10.77 8.85 8.02 8.28 6.88 9.05 10.21 8.51 6.52
Cash ratio 6.94 8.62 8.83 9.25 11.34 8.77 9.11 6.56 5.91 5.67 11.84 14.87 14.88 9.39 10.64 8.65 7.72 7.87 6.72 8.95 9.79 8.50 6.52

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

Liquidity ratio Description The company
Current ratio A liquidity ratio calculated as current assets divided by current liabilities. Cytokinetics Inc. current ratio deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.
Quick ratio A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. Cytokinetics Inc. quick ratio deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.
Cash ratio A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. Cytokinetics Inc. cash ratio deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.

Current Ratio

Cytokinetics Inc., current ratio calculation (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Selected Financial Data (US$ in thousands)
Current assets 561,416 586,575 680,629 795,186 884,275 602,250 623,526 535,672 494,941 364,229 433,117 474,221 418,412 218,954 225,938 233,752 176,535 184,951 186,400 207,674 227,269 244,229 272,339
Current liabilities 77,723 65,617 75,220 84,617 76,496 66,843 66,847 71,860 80,868 61,766 35,930 31,199 27,573 22,696 20,741 26,023 21,517 21,959 26,277 22,194 21,492 27,289 38,546
Liquidity Ratio
Current ratio1 7.22 8.94 9.05 9.40 11.56 9.01 9.33 7.45 6.12 5.90 12.05 15.20 15.17 9.65 10.89 8.98 8.20 8.42 7.09 9.36 10.57 8.95 7.07
Benchmarks
Current Ratio, Competitors2
AbbVie Inc. 0.96 0.89 0.96 0.96 0.93 0.84 0.82 0.79 1.01 0.91 0.83 0.84 0.95 0.86 3.14 3.18 1.15 0.89 1.04
Amgen Inc. 2.86 2.77 3.14 1.41 1.68 1.53 1.44 1.59 1.64 1.31 1.66 1.81 2.28 2.18 1.59 1.44 2.89 2.89 2.77
Bristol-Myers Squibb Co. 1.18 1.39 1.42 1.25 1.42 1.44 1.32 1.52 1.47 1.54 1.56 1.58 1.67 1.47 1.66 1.60 3.83 3.88 1.93
Danaher Corp. 2.26 2.08 1.89 1.89 1.78 1.75 1.68 1.43 1.48 2.26 2.05 1.86 2.08 2.20 1.32 5.19 3.43 2.32 2.18
Eli Lilly & Co. 1.05 1.13 1.30 1.05 1.13 1.10 1.27 1.23 1.30 1.15 1.42 1.40 1.36 1.22 1.11 1.16 1.17 1.13 1.12
Gilead Sciences Inc. 1.34 1.02 1.28 1.29 1.30 1.43 1.48 1.27 1.37 1.36 1.37 1.40 3.25 2.33 3.04 3.10 2.96 3.76 3.62
Johnson & Johnson 1.21 1.12 1.07 0.99 1.43 1.42 1.39 1.35 1.34 1.39 1.28 1.21 1.48 1.25 1.31 1.26 1.26 1.33 1.44
Merck & Co. Inc. 1.38 1.28 1.44 1.47 1.46 1.39 1.40 1.27 1.31 1.31 1.02 1.02 1.30 1.32 1.11 1.24 1.26 1.21 1.37
Moderna Inc. 2.46 3.39 3.46 2.73 2.10 1.99 1.77 1.76 1.35 1.24 1.39 1.43 2.43 17.30 9.29 7.89 7.40 6.77 7.17
Pfizer Inc. 2.38 2.12 1.37 1.22 1.59 1.42 1.39 1.40 1.39 1.37 1.48 1.35 1.40 1.42 1.03 0.88 0.90 1.47 1.54
Regeneron Pharmaceuticals Inc. 5.18 5.45 5.45 5.06 5.36 5.12 4.76 3.56 3.71 3.57 3.12 3.63 3.89 2.12 4.21 3.67 4.03 3.88 4.58
Thermo Fisher Scientific Inc. 1.63 1.42 1.27 1.48 1.74 1.65 1.56 1.50 3.19 2.78 2.53 2.13 2.93 2.62 2.32 1.92 1.80 1.49 1.69

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Q3 2023 Calculation
Current ratio = Current assets ÷ Current liabilities
= 561,416 ÷ 77,723 = 7.22

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Current ratio A liquidity ratio calculated as current assets divided by current liabilities. Cytokinetics Inc. current ratio deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.

Quick Ratio

Cytokinetics Inc., quick ratio calculation (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Selected Financial Data (US$ in thousands)
Cash and cash equivalents 99,692 68,639 101,616 65,582 106,238 93,631 115,422 112,666 90,562 37,154 44,594 82,985 200,812 61,134 49,776 36,433 39,634 34,361 39,409 42,256 27,624 46,955 115,011
Short-term investments 439,547 497,083 562,346 716,995 761,426 492,395 493,552 358,972 387,074 313,147 380,983 381,075 209,452 151,929 170,930 188,679 126,405 138,507 137,213 156,475 182,686 184,986 136,443
Accounts receivable 2,499 985 1,006 147 2,294 1,973 6,056 51,819 644 2,701 4,514 4,420 4,965 2,254 2,704 5,163 6,576 8,993 4,165 2,231 9,156 236 37
Total quick assets 541,738 566,707 664,968 782,724 869,958 587,999 615,030 523,457 478,280 353,002 430,091 468,480 415,229 215,317 223,410 230,275 172,615 181,861 180,787 200,962 219,466 232,177 251,491
 
Current liabilities 77,723 65,617 75,220 84,617 76,496 66,843 66,847 71,860 80,868 61,766 35,930 31,199 27,573 22,696 20,741 26,023 21,517 21,959 26,277 22,194 21,492 27,289 38,546
Liquidity Ratio
Quick ratio1 6.97 8.64 8.84 9.25 11.37 8.80 9.20 7.28 5.91 5.72 11.97 15.02 15.06 9.49 10.77 8.85 8.02 8.28 6.88 9.05 10.21 8.51 6.52
Benchmarks
Quick Ratio, Competitors2
AbbVie Inc. 0.71 0.63 0.66 0.69 0.69 0.61 0.56 0.56 0.75 0.65 0.61 0.60 0.68 0.58 2.88 2.91 0.92 0.64 0.78
Amgen Inc. 2.41 2.34 2.62 0.95 1.17 0.99 0.90 1.06 1.19 0.86 1.16 1.30 1.65 1.60 1.10 1.01 2.28 2.41 2.37
Bristol-Myers Squibb Co. 0.77 0.94 1.01 0.87 0.98 1.07 1.03 1.20 1.16 1.16 1.25 1.28 1.43 1.26 1.38 1.26 3.63 3.61 1.64
Danaher Corp. 1.76 1.52 1.34 1.30 1.19 1.13 1.08 0.89 0.93 1.67 1.51 1.36 1.52 1.59 0.92 4.68 2.99 1.78 1.58
Eli Lilly & Co. 0.58 0.63 0.79 0.63 0.71 0.67 0.77 0.80 0.79 0.67 0.83 0.85 0.79 0.68 0.64 0.68 0.66 0.67 0.65
Gilead Sciences Inc. 0.98 0.78 0.95 0.99 0.96 1.06 1.06 0.95 1.01 1.05 0.99 1.08 2.93 2.09 2.78 2.86 2.74 3.41 3.32
Johnson & Johnson 0.86 0.84 0.81 0.71 1.10 1.09 1.06 1.04 1.03 1.04 0.97 0.91 1.17 0.92 0.98 0.94 0.93 0.95 1.01
Merck & Co. Inc. 0.83 0.74 0.90 0.93 0.90 0.85 0.84 0.73 0.78 0.75 0.58 0.58 0.77 0.84 0.66 0.78 0.80 0.75 0.88
Moderna Inc. 2.15 2.78 2.87 2.29 1.62 1.55 1.44 1.52 1.21 1.13 1.30 1.37 2.35 17.01 9.10 7.74 7.22 6.64 7.01
Pfizer Inc. 1.78 1.59 0.88 0.80 1.18 1.02 0.95 1.00 0.99 0.91 0.88 0.78 0.93 0.98 0.60 0.50 0.50 0.71 0.72
Regeneron Pharmaceuticals Inc. 4.31 4.53 4.54 4.16 4.37 4.20 3.95 2.98 3.03 2.92 2.39 2.86 3.02 1.61 3.38 2.81 3.14 2.99 3.66
Thermo Fisher Scientific Inc. 1.13 0.89 0.80 1.06 1.06 0.98 0.97 1.00 2.37 1.92 1.70 1.63 2.16 1.83 1.48 1.19 0.97 0.85 0.89

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Q3 2023 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= 541,738 ÷ 77,723 = 6.97

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Quick ratio A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. Cytokinetics Inc. quick ratio deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.

Cash Ratio

Cytokinetics Inc., cash ratio calculation (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Selected Financial Data (US$ in thousands)
Cash and cash equivalents 99,692 68,639 101,616 65,582 106,238 93,631 115,422 112,666 90,562 37,154 44,594 82,985 200,812 61,134 49,776 36,433 39,634 34,361 39,409 42,256 27,624 46,955 115,011
Short-term investments 439,547 497,083 562,346 716,995 761,426 492,395 493,552 358,972 387,074 313,147 380,983 381,075 209,452 151,929 170,930 188,679 126,405 138,507 137,213 156,475 182,686 184,986 136,443
Total cash assets 539,239 565,722 663,962 782,577 867,664 586,026 608,974 471,638 477,636 350,301 425,577 464,060 410,264 213,063 220,706 225,112 166,039 172,868 176,622 198,731 210,310 231,941 251,454
 
Current liabilities 77,723 65,617 75,220 84,617 76,496 66,843 66,847 71,860 80,868 61,766 35,930 31,199 27,573 22,696 20,741 26,023 21,517 21,959 26,277 22,194 21,492 27,289 38,546
Liquidity Ratio
Cash ratio1 6.94 8.62 8.83 9.25 11.34 8.77 9.11 6.56 5.91 5.67 11.84 14.87 14.88 9.39 10.64 8.65 7.72 7.87 6.72 8.95 9.79 8.50 6.52
Benchmarks
Cash Ratio, Competitors2
AbbVie Inc. 0.38 0.27 0.24 0.31 0.36 0.29 0.23 0.28 0.43 0.30 0.31 0.30 0.33 0.25 2.50 2.56 0.61 0.32 0.38
Amgen Inc. 2.05 2.00 2.22 0.59 0.80 0.57 0.51 0.66 0.87 0.55 0.82 0.91 1.24 1.09 0.68 0.69 1.94 2.05 2.07
Bristol-Myers Squibb Co. 0.33 0.43 0.49 0.42 0.48 0.63 0.66 0.78 0.73 0.68 0.75 0.83 1.03 0.92 0.95 0.84 3.10 3.02 0.99
Danaher Corp. 1.31 1.02 0.85 0.71 0.64 0.53 0.49 0.32 0.35 1.07 0.93 0.82 0.94 0.99 0.52 4.04 2.40 1.08 0.84
Eli Lilly & Co. 0.11 0.15 0.23 0.13 0.18 0.18 0.19 0.26 0.28 0.22 0.26 0.29 0.30 0.20 0.14 0.21 0.15 0.20 0.19
Gilead Sciences Inc. 0.57 0.48 0.56 0.57 0.54 0.61 0.62 0.56 0.56 0.64 0.58 0.65 2.52 1.79 2.34 2.50 2.39 3.03 2.97
Johnson & Johnson 0.53 0.53 0.54 0.42 0.75 0.73 0.70 0.70 0.70 0.65 0.60 0.59 0.79 0.52 0.54 0.54 0.51 0.49 0.53
Merck & Co. Inc. 0.38 0.27 0.45 0.54 0.49 0.44 0.40 0.34 0.42 0.39 0.26 0.30 0.36 0.50 0.32 0.47 0.39 0.35 0.47
Moderna Inc. 1.73 2.71 2.55 2.01 1.23 1.16 1.09 1.18 0.89 0.90 0.92 1.05 2.22 16.81 9.05 7.71 7.16 6.61 6.97
Pfizer Inc. 1.42 1.29 0.55 0.54 0.82 0.70 0.61 0.73 0.71 0.61 0.51 0.47 0.64 0.70 0.31 0.26 0.25 0.40 0.39
Regeneron Pharmaceuticals Inc. 2.75 2.88 2.89 2.46 2.44 2.49 2.34 1.45 1.56 1.05 1.09 1.33 1.29 0.85 1.95 1.53 1.63 1.56 2.14
Thermo Fisher Scientific Inc. 0.43 0.22 0.22 0.50 0.26 0.17 0.23 0.33 1.55 1.01 0.80 1.00 1.21 0.97 0.54 0.39 0.22 0.30 0.19

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Q3 2023 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= 539,239 ÷ 77,723 = 6.94

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Cash ratio A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. Cytokinetics Inc. cash ratio deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.